Conference attendances

RNS Number : 6703Y
Polarean Imaging PLC
14 May 2021
 

Polarean Imaging plc

("Polarean" or the "Company")

 

Scientific presentations on hyperpolarised Xenon-129 at upcoming medical conferences

Polarean's investigational drug/device combination product to be prominently featured in presentations across a wide range of lung diseases

 

Polarean Imaging plc (AIM: POLX), the medical - imaging technology company, with an investigational drug - device combination product to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces a number of abstracts and oral presentations highlighting the use of hyperpolarised Xenon-129 ("129Xe") will be made by leading academic researchers at the upcoming American Thoracic Society ("ATS 2021") virtual conference from 14-19 May 2021 and the International Society for Magnetic Resonance in Medicine ("ISMRM 2021") virtual conference from 15-20 May 2021.

 

23 abstracts related to the use of hyperpolarised 129Xe were accepted for presentation at ATS 2021, consisting of 8 oral presentations and 15 e-poster presentations. Polarean is also supporting ATS 2021 by hosting a virtual exhibit booth.

 

Additionally, 34 abstracts related to the use of hyperpolarised 129Xe were accepted for presentation at ISMRM 2021, consisting of 7 oral presentations and 27 e-poster presentations. Hyperpolarised 129Xe will also be discussed in a symposium on 17 May and in a sunrise session on 18 May. Furthermore, Polarean is supporting ISMRM 2021 by hosting a virtual exhibit booth. 

 

Richard Hullihen, Chief Executive Officer of Polarean commented:   "We are pleased at the important work being done by leading investigators in the field of functional lung imaging. The data being presented at these key scientific meetings will further add to the body of evidence on hyperpolarised 129Xenon, highlighting several areas of unmet needs in current diagnostic modalities. Research of 129Xe MRI in interstitial lung disease, long-COVID-19, asthma, COPD and interventional pulmonology procedures are among the presentations that will be showcased."

 

A subset of the abstracts that will be presented during the ATS 2021 and ISMRM conferences are listed below.

 

Lead Author and ATS Abstract Title

Presentation Date

Abstract Number

ATS Notes

Mummy D et al.
Regional Changes in Ventilation Following Bronchodilation in COPD Are Not Associated with Improved Gas Exchange on Xenon-129 MRI

16-May

1052

ORAL PRESENTATION
Session A12: Sunday, May 16, 2021 (3:30-5pm)

Mcintosh M et al.
Response to Benralizumab in Severe Asthma: Oscillometry and MRI Ventilation Defect Improvements in Participants with Abnormal FeNO

18-May

1111

ORAL PRESENTATION
Session C4: Tuesday, May 18, 2021 (8-9:30am)

Eddy RL et al.
Structure-Function Imaging Phenotypes of Asthma Using CT and 129Xe MRI

18-May

1112

ORAL PRESENTATION
Session C4: Tuesday, May 18, 2021 (8-9:30am)

HE M et al.
Probing Early-Stage Pulmonary Pathophysiology in Young Healthy E-cigarettes Users Using Hyperpolarized 129Xe MRI

18-May

1113

ORAL PRESENTATION
Session C4: Tuesday, May 18, 2021 (8-9:30am)

Bdaiwi, AS et al.
In Vivo Lung Morphometry of Lymphangioleiomyomatosis Using Hyperpolarized 129Xe Diffusion MRI

18-May

1114

ORAL PRESENTATION
Session C4: Tuesday, May 18, 2021 (8-9:30am)

Bier E et al.
Hyperpolarized 129Xe Magnetic Resonance Oscillation Imaging in Pulmonary Hypertension

18-May

1115

ORAL PRESENTATION
Session C4: Tuesday, May 18, 2021 (8-9:30am)

Mummy D et al.
Hyperpolarized 129Xe MRI Features Identify Functional Differences That Do Not Correlate with Chest CT in Patients with Idiopathic Pulmonary Fibrosis

18-May

1116

ORAL PRESENTATION
Session C4: Tuesday, May 18, 2021 (8-9:30am)

Plummer JW et al.
129Xe gas-exchange MRI to detect diffusion abnormalities in children following bone-marrow transplantation

18-May

1166

ORAL PRESENTATION
Session C15: Tuesday, May 18, 2021 (3:30-5pm)

Ruppert K et al.
First Experience with Hyperpolarized 129Xe Imaging in a Recovered COVID-19 Patient

May 14-19

1998

E-poster
Session TP031

 

Ranota TK et al.
The Use of Hyper-polarized 129Xe Pulmonary MRI for Study of the Lung Damage in COVID-19 Survivors, Preliminary Results

May 14-19

3835

E-poster
Session TP92

Matheson AM et al.
This Is What COVID-19 Survival Looks Like: 129Xe MRI, Oscillometry and Pulmonary Function Measurements

May 14-19

4453

E-poster
Session TP117

Kooner HK et al.
CT Mucus Score Predicts Benralizumab Response in Severe Asthma

May 14-19

4531

E-poster
Session TP120

Woodward E et al.
Four Years Observation of the Emphysema Progression in Alpha-1 Antitrypsin Deficiency Using 3He/129Xe MRI

May 14-19

4574

E-poster
Session TP121

Hamedani H et al.
Monitoring Patients with Endobronchial Valve Interventions Using a Multifaceted Hyperpolarized (HP) Xenon Lung Function Assessment

May 14-19

4578

E-poster
Session TP121

Bier E et al.
Within-session Repeatability of Pulmonary 129Xe Static and Dynamic Spectroscopy

May 14-19

4589

E-poster
Session TP122

Amzajerdian F et al.
Exploring the Use of Continuous RF Irradiation for Xenon Polarization Transfer Contrast Imaging

May 14-19

4590

E-poster
Session TP122

 

 

Lead Author and ISMRM Abstract Title

Presentation Date

Abstract Number

ISMRM Notes

Leewiwatwong S et al.
Deep learning-based thoracic cavity segmentation for hyperpolarized 129Xe MRI

18-May

391

ORAL PRESENTATION
(Session: Machine Learning for Image Analysis)

Mummy D et al.
Regional Changes in Ventilation Following Bronchodilation in COPD Are Not Associated With Improved Gas Exchange on Xenon-129 MRI

19-May

589

ORAL PRESENTATION
(Session: Lung)

Hahn A et al.
Response of Hyperpolarized 129Xe MRI measures of ventilation and gas-exchange to anti-fibrotic treatment in Idiopathic Pulmonary Fibrosis

19-May

591

ORAL PRESENTATION
(Session: Lung)

Hamedani H et al.
Monitoring Patients with Endobronchial Valve Interventions Using a Multifaceted Hyperpolarized Xenon Lung Function Assessment

19-May

592

ORAL PRESENTATION
(Session: Lung)

Marshall H et al.
Hyperpolarised xenon ventilation MRI in difficult asthma; initial experience in a clinical setting

20-May

680

ORAL PRESENTATION
(Session: Latest Advances in Hyperpolarized MRI)

Bier E et al.
Extension of a Diagnostic Model for Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance Imaging and Spectroscopy

20-May

681

ORAL PRESENTATION
(Session: Latest Advances in Hyperpolarized MRI)

Albert B J et al.
Preclinical Hyperpolarized 129Xe Ventilation Imaging Using 3D Spiral (FLORET) Encoding

20-May

684

ORAL PRESENTATION
(Session: Latest Advances in Hyperpolarized MRI)

Rao M.
Imaging Beyond Perfusion Using 129Xe MRI

17-May


MEMBER-INITIATED SYMPOSIUM
(Imaging Beyond Perfusion Using 129Xe MRI)

Woodward E et al.
The Use of the 3He/129Xe MRI Lung Morphometry for a Longitudinal Observation of the Emphysema Progression in AATD Patients

17-May

1269

E-poster
(Session: Novel Contrast Mechanisms)

Grist J et al.
Utilizing hyperpolarised xenon MRI to detect gas transport deficiencies in post-COVID lungs

17-May

1736

E-poster
(Session: MRI in COVID-19)

Ranota T et al.
Feasibility of Single Breath-hold Isotropic Voxel 129Xe MRI in COVID-19 Survivors using a Key-Hole Method

17-May

1739

E-poster
(Session: Role of Advanced Imaging in COVID-19)

Collier G et al.
Imaging lung structure and function in acute COVID-19 patients with 129Xe and 1H MRI

17-May

1746

E-poster
(Session: Role of Advanced Imaging in COVID-19)

Wild J.
Hyperpolarized 129Xe MRI of the Lung

18-May


SUNRISE SESSION
(Lung MRI: You Can Do It!)

Lu T et al.
Convolutional Neural Networks for Super-resolution of Hyperpolarized 129Xe MR Images of the Lung

18-May

1968

E-poster
(Session: Machine Learning to Reconstruct Accelerated Scans)

Gandhi D B et al.
Comparison of Respiratory-Gating Weighting Algorithms in Neonatal Pulmonary UTE-MRI

18-May

2273

E-poster
(Session: Pediatrics: Body Topics)

Chan H-F et al.
Comparison of UTE 1H lung MRI with quantitative CT and hyperpolarized 129Xe diffusion-weighted MRI in IPF

19-May

3214

E-poster
(Session: Lung: Disease Assessment)

Eaden J et al.
Correlation of global and regional hyperpolarised 129-Xenon MRI with quantitative CT in patients with idiopathic pulmonary fibrosis

19-May

3216

E-poster
(Session: Lung Disease Assessment)

Bdaiwi A S et al.
Optimizing Acquisition and Analysis for Diffusion Weighted Hyperpolarized 129Xe MRI of Pediatric and Adult Lungs

20-May

3558

E-poster
(Session: Hyperpolarization: Gas)

Astley J et al.
Comparison of 3D convolutional neural networks and loss functions for ventilated lung segmentation using multi-nuclear hyperpolarized gas MRI

20-May

3560

E-poster
(Session: Hyperpolarization: Gas)

Schulte R et al.
Imaging Gas-Exchange Lung Function using Density-Weighted MRSI and Hyperpolarised 129Xe Gas

20-May

3562

E-poster
(Session: Hyperpolarization: Gas)

Pratt R et al.
A 129Xe/1H Switched Frequency High Pass Birdcage Coil for Hyperpolarized 129Xe Gas Lung Imaging in Neonates at 1.5 T

20-May

3563

E-poster
(Session: Hyperpolarization: Gas)

Norquay G et al.
Temporal correlation of alveolar-capillary 129Xe signal dynamics with the cardiac cycle

20-May

3564

E-poster
(Session: Hyperpolarization: Gas)

Amzajerdian F et al.
Feasibility of Xenon Polarization Transfer Contrast Imaging using Continuous RF Irradiation

20-May

3565

E-poster
(Session: Hyperpolarization: Gas)

Hamedani H et al.
Reproducibility Study Measuring Ventilation, Gas Exchange and Surface-to-Volume Using Hyperpolarized Xenon in Free-breathing Human Subjects

20-May

3566

E-poster
(Session: Hyperpolarization: Gas)

Rao M et al.
3D isotropic spectroscopic imaging of hyperpolarized 129Xe in the human brain

20-May

3567

E-poster
(Session: Hyperpolarization: Gas)

Chan H-F et al.
Background field inhomogeneity effects on hyperpolarized 129Xe diffusion-weighted MRI at 1.5T and 3T

20-May

3568

E-poster
(Session: Hyperpolarization: Gas)

Ruppert K et al.
Detection of pulmonary abnormalities in a rabbit thoracic insufficiency syndrome model using hyperpolarized xenon-129 MRI

20-May

3569

E-poster
(Session: Hyperpolarization: Gas)

Ball G et al.
Modelling realistic Rb density and temperature distributions in a high throughput xenon-129 polariser

20-May

3570

E-poster
(Session: Hyperpolarization: Gas)

Lu J et al.
Template-based bias field correction of Hyperpolarized 129Xe Gas Ventilation MRI

20-May

3571

E-poster
(Session: Hyperpolarization: Gas)

Bdaiwi A S et al.
2D and 3D Spiral for Diffusion Weighted MRI with Hyperpolarized 129Xe

20-May

3575

E-poster
(Session: Hyperpolarization: Gas)

Driehuys B et al.
Establishing the Structurally Limited Healthy RBC to Barrier Ratio for 129Xe Gas Exchange MRI

20-May

3791

E-poster
(Session: Hyperpolarization: Gas & Non-Gas)

Bier E et al.
Within-session Repeatability of Pulmonary 129Xe Static and Dynamic Spectroscopy

20-May

3792

E-poster
(Session: Hyperpolarization: Gas & Non-Gas)

Doganay O et al.
Assessment of Gas Exchange Parameters in Healthy and COPD Subjects using Hyperpolarized Xenon-129 MRI and Alveolar Gas-exchange Model

20-May

3793

E-poster
(Session: Hyperpolarization: Gas & Non-Gas)

Loza L et al.
A Comparison of Multi-breath Wash-in/Wash-out and RF-Contrast Hyperpolarized 129Xe Imaging Schemes for Quantifying Fractional Ventilation

20-May

3794

E-poster
(Session: Hyperpolarization: Gas & Non-Gas)

Costa M L et al.
Optimized Magnetization Decay Correction of Hyperpolarized Xe Ventilation Images Using Radial-Keyhole

20-May

3795

E-poster
(Session: Hyperpolarization: Gas & Non-Gas)

Qian Y et al.
Simulating the impact of asymmetric geometries on apparent alveolar septal wall thickness measurements with hyperpolarized xenon-129 MRI

20-May

3796

E-poster
(Session: Hyperpolarization: Gas & Non-Gas)

 

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Jonathan Allis, Chairman




Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)


Nick Adams / Fred Walsh (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

 

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASFASALEFSEFI
UK 100

Latest directors dealings